Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Insmed (INSM) has announced the granting of inducement awards to 66 new employees as approved by its Compensation Committee, in compliance with NASDAQ Listing Rule 5635(c)(4). On February 3, 2025, the employees received options to purchase a total of 108,860 shares of Insmed common stock at an exercise price of $77.88 per share, which was the closing price on the Nasdaq Global Select Market on the grant date.
The stock options come with a 10-year term and a four-year vesting schedule. The vesting terms include 25% of shares vesting on the first anniversary of the grant date, followed by 12.5% vesting every six months through the fourth anniversary, contingent upon continued employment with Insmed.
Insmed (INSM) ha annunciato l'assegnazione di premi di indennizzo a 66 nuovi dipendenti, come approvato dal suo Comitato Compensi, in conformità con la Regola di Listaggio NASDAQ 5635(c)(4). Il 3 febbraio 2025, i dipendenti hanno ricevuto opzioni per acquistare un totale di 108.860 azioni delle azioni comuni di Insmed a un prezzo di esercizio di 77,88 $ per azione, che corrispondeva al prezzo di chiusura sul Nasdaq Global Select Market nella data di assegnazione.
Le opzioni sulle azioni hanno un termine di 10 anni e un programma di maturazione di quattro anni. I termini di maturazione prevedono che il 25% delle azioni matura al primo anniversario della data di assegnazione, seguito dal 12,5% che matura ogni sei mesi fino al quarto anniversario, a condizione di continuare a lavorare con Insmed.
Insmed (INSM) ha anunciado la concesión de premios de inducción a 66 nuevos empleados, como fue aprobado por su Comité de Compensación, en cumplimiento con la Regla de Cotización NASDAQ 5635(c)(4). El 3 de febrero de 2025, los empleados recibieron opciones para comprar un total de 108,860 acciones de acciones ordinarias de Insmed a un precio de ejercicio de $77.88 por acción, que era el precio de cierre en el Nasdaq Global Select Market en la fecha de concesión.
Las opciones sobre acciones tienen un plazo de 10 años y un programa de adquisición de cuatro años. Los términos de adquisición incluyen el 25% de las acciones que se adquieren en el primer aniversario de la fecha de concesión, seguido del 12.5% que se adquiere cada seis meses hasta el cuarto aniversario, sujeto a la continuación del empleo en Insmed.
인스메드 (INSM)는 NASDAQ 상장 규정 5635(c)(4)에 따라 보상 위원회의 승인을 받아 66명의 신입 직원을 위한 유인상 여정의 수여를 발표했습니다. 2025년 2월 3일, 직원들은 인스메드의 보통주 108,860주를 $77.88의 행사가로 구매할 수 있는 옵션을 받았습니다. 이는 부여일의 나스닥 글로벌 셀렉트 마켓에서의 종가입니다.
주식 옵션은 10년의 기간과 4년의 취득 일정을 가지고 있습니다. 취득 조건은 부여일의 첫 번째 기념일에 25%의 주식이 취득되고, 이후 4년 기념일까지 매 6개월마다 12.5%씩 취득되는 것으로, 인스메드에서 계속 고용되는 것에 따라 달라집니다.
Insmed (INSM) a annoncé l'octroi de primes d'incitation à 66 nouveaux employés, approuvé par son Comité de Rémunération, conformément à la Règle d'Énumération NASDAQ 5635(c)(4). Le 3 février 2025, les employés ont reçu des options d'achat d'un total de 108 860 actions de l'action ordinaire d'Insmed à un prix d'exercice de 77,88 $ par action, qui correspondait au prix de clôture sur le Nasdaq Global Select Market à la date d'octroi.
Les options d'achat d'actions ont un terme de 10 ans et un calendrier d'acquisition de quatre ans. Les conditions d'acquisition incluent 25 % des actions acquises à l'anniversaire de la date d'octroi, suivies de 12,5 % acquises tous les six mois jusqu'au quatrième anniversaire, sous réserve de la poursuite de l'emploi chez Insmed.
Insmed (INSM) hat die Vergabe von Anreizprämien an 66 neue Mitarbeiter angekündigt, wie von seinem Vergütungsausschuss genehmigt, in Übereinstimmung mit der NASDAQ-Börsenvorschrift 5635(c)(4). Am 3. Februar 2025 erhielten die Mitarbeiter Optionen zum Kauf von insgesamt 108.860 Aktien der Stammaktien von Insmed zu einem Ausübungspreis von 77,88 $ pro Aktie, was dem Schlusskurs am Grant-Datum an der Nasdaq Global Select Market entsprach.
Die Aktienoptionen haben eine Laufzeit von 10 Jahren und einen Vesting-Zeitplan von vier Jahren. Die Vesting-Bedingungen sehen vor, dass 25% der Aktien am ersten Jahrestag des Zuteilungsdatums fällig werden, gefolgt von 12,5% alle sechs Monate bis zum vierten Jahrestag, vorausgesetzt, die Beschäftigung bei Insmed bleibt bestehen.
- Expansion of workforce with 66 new employees indicating company growth
- Alignment of employee interests with shareholders through equity compensation
- Potential dilution of existing shareholders due to 108,860 new stock options
In connection with the commencement of their employment, the employees received options on February 3, 2025 to purchase an aggregate 108,860 shares of Insmed common stock at an exercise price of
The options have a 10-year term and a four-year vesting schedule, with
About Insmed
Insmed Incorporated is a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases. The Company is advancing a diverse portfolio of approved and mid- to late-stage investigational medicines as well as cutting-edge drug discovery focused on serving patient communities where the need is greatest. Insmed's most advanced programs are in pulmonary and inflammatory conditions, including a therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. The Company's early-stage research programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue.
Headquartered in Bridgewater,
Contact:
Investors:
Bryan Dunn
Vice President, Investor Relations
(646) 812-4030
bryan.dunn@insmed.com
Michael V. Morabito, Ph.D.
Director, Investor Relations
(917) 936-8430
michael.morabito@insmed.com
Gianna De Palma
Manager, Investor Relations
(973) 886-2236
gianna.depalma@insmed.com
Media:
Mandy Fahey
Vice President, Corporate Communications
(732) 718-3621
amanda.fahey@insmed.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-302370675.html
SOURCE Insmed Incorporated
FAQ
How many shares were granted in Insmed's (INSM) February 2025 inducement awards?
What is the exercise price for Insmed's (INSM) February 2025 inducement stock options?
What is the vesting schedule for Insmed's (INSM) February 2025 inducement options?
How long is the term of Insmed's (INSM) February 2025 inducement stock options?
